About
Multi-Stage Malaria Vaccine Consortium (MMVC)
The Multi-Stage Malaria Vaccine Consortium. MMVC, will test a multi-stage vaccine in a large phase IIb efficacy trial in West and East African infants. The four components of the vaccine have strong validation in clinical trials. MMVC will undertake a tightly co-ordinated series of lead-in trials in 2018-2021 building towards a phase IIb efficacy trial in infants from late 2021 to 2023. In parallel MMVC will build new capacity to test the ability of the combination vaccine and/or its transmission-blocking component to block human-to-mosquito transmission in African adults, foreseeing the potential use of the combination vaccine in elimination campaigns. This consortium, comprising very experienced and new African trial sites with leading northern institutions and companies, offers an unprecedented opportunity for rapid development of a deployable high-efficacy multi-stage malaria vaccine.
TARGET DISEASE: Malaria | multi-stage
TIMELINE: 01 April 2018 to 30 September 2023
COORDINATOR: University of Oxford
FUNDER: EDCTP
FUNDING: € 15 Mio
Contact details
Please sign in to see contact details.
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views
- Comments 0